DEMECAN founder Dr. Maurer joins the supervisory board and hands over operational responsibility to former Merck manager Dr. Goebel
Berlin/Dresden, 09. March 2022 – The imminent legalization of cannabis for recreational purposes opens up new business opportunities for DEMECAN, the only independent German producer of medical cannabis. To seize the opportunities, the company is reorganizing its management and supervisory board. In the future, Dr. Cornelius Maurer will drive strategic topics from the supervisory board, and focus on the legalization of recreational cannabis, German cannabis association work and capital acquisition. With Dr. Philipp Goebel the cannabis producer is gaining further expertise from the pharmaceutical sector and a proven specialist in pharmaceutical sales, marketing and supply chain management to the management board.
DEMECAN is the only independent German cannabis producer supplying patients in Germany with cannabis flowers from its own EU-GMP certified facility near Dresden. As a wholesaler, DEMECAN also imports medicinal cannabis flowers and extracts from abroad. DEMECAN was founded in 2017 by Dr. Cornelius Maurer, Dr. Adrian Fischer and Dr. Constantin von der Groeben. The trio has built the Berlin-based startup into Germany's most successful cannabis producers and cannabis wholesaler.
With the commissioning of Europe's largest indoor production facility for cannabis and the upcoming first cannabis delivery to the Federal Institute for Drugs and Medical Devices (BfArM), the founders are opening a new chapter in the company's history. For founder Dr. Maurer this is the ideal time for a change to the supervisory board and a strategic reorientation. In the future, he will focus on the strategically important topics such as legalization of cannabis for recreational usage, cannabis association work and capital acquisition. At the same time, he will turn to new operational challenge: As founder and managing director, Dr. Cornelius Maurer will lead 420 Venture Capital GmbH from Berlin.
"My understanding as a founder is to get ideas off the ground, create values, and develop a solid foundation for a long-term successful company. DEMECAN is a success story and I am more than proud of the performance, creativity and passionate commitment of our entire team. Five years after its foundation, DEMECAN has established itself as the only independent producer and wholesaler of medical cannabis in Germany and it is the right time for me to fully focus on strategic topics in the future, such as the emerging stimulant market for recreational cannabis, cannabis association work and fundraising ", explains Dr. Cornelius Maurer.
Focus on the growing demand for cannabis in Germany
Dr. Philipp Goebel, an experienced executive for pharmaceutical sales and marketing as well as supply chain management, takes over the operational responsibility as managing director for procurement, product strategy, sales and marketing of DEMECAN. In his previous role at Merck, the world's oldest pharmaceutical company, he was responsible for the business unit Neurology & Immunology. Dr. Goebel's prior sales and marketing experience in oncology and neurology, key application areas of medical cannabis, complements the expertise of the entire management team and ensures a continuation of the rapid growth of DEMECAN.
"The step that Dr. Cornelius Maurer has now taken is not easy for any founder. It is a sign of great strength and leadership quality to hand over the operational responsibility of our company and to focus on strategic topics from now on as a shareholder and supervisory board member. The development of the past five years under Dr. Cornelius Maurer has been tremendous, and DEMECAN is in an ideal position to become the German market leader for medical and recreational cannabis due to our modular expandable production capacities, our focus on continuous research and development of new flower products, the broad supplier base as well as the strong distribution channels. With the help of managing director Dr. Philipp Goebel and his experience in the pharmaceutical and logistic sector, we will take DEMECAN to the next level of development," explains Dr. Constantin von der Groeben, founder and managing director at DEMECAN.
Co-founders Dr. Constantin von der Groeben and Dr. Adrian Fischer as well as Jörg Sellmann will remain operationally active in the company as managing directors.
About DEMECAN
DEMECAN is the only independent German company that covers the entire value chain for medical cannabis - from cultivation to processing and storage to distribution to pharmacies. The company was founded in 2017 by Dr. Adrian Fischer, Dr. Cornelius Maurer and Dr. Constantin von der Groeben with the aim of guaranteeing patients access to medical cannabis in "Made in Germany" quality. In May 2019, DEMECAN was awarded a state contract by the Federal Institute for Drugs and Medical Devices (BfArM) as the only independent German company to cultivate and distribute medical cannabis in Germany. Cultivation and further processing are carried out according to the highest pharmaceutical standards (EU-GMP) at the company's facility near Dresden. As a pharmaceutical wholesaler, DEMECAN works with cannabis producers worldwide and imports medical cannabis that meets its own high quality standards. The DEMECAN Group is a member of the Federal Association of Pharmaceutical Cannabinoid Companies (BPC) and a supporting member of the Association of Pharmacies Supplying Cannabis (VCA e.V.).
Further Information: www.demecan.de
Press contact: press@demecan.de
